Cardiac resynchronization therapy indications

Revision as of 17:52, 12 September 2011 by Kristin Feeney (talk | contribs) (New page: {{Cardiac resynchronization therapy}} {{CMG}}; {{AOEIC}}: Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com] '''''Synonyms and Keywords:''''' CRT ==Overview== ==Indications== The ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Cardiac resynchronization therapy Microchapters

Home

Overview

Indications

Landmark Trials

Contraindications

Pathophysiologic Basis for CRT

Treatment

Preoperative Evaluation

Procedure

Recovery

Outcomes and Prognosis

Complications

Cardiac resynchronization therapy indications On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac resynchronization therapy indications

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac resynchronization therapy indications

CDC on Cardiac resynchronization therapy indications

Cardiac resynchronization therapy indications in the news

Blogs on Cardiac resynchronization therapy indications

Directions to Hospitals Administering Cardiac resynchronization therapy

Risk calculators and risk factors for Cardiac resynchronization therapy indications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief:: Bhaskar Purushottam, M.D. [2] Synonyms and Keywords: CRT

Overview

Indications

The ACC / AHA guidelines indicate that CRT is recommended for those patients with all of the following: [1]

1. Patients with an left ventricular ejection fraction less than or equal to 35%, QRS duration greater than or equal to 0.12 seconds, sinus rhythm and NYHA class 3 or 4 heart failure symptoms on optimal medical therapy (considered a class 1 indication with level A evidence)

2. Patients with an left ventricular ejection fraction less than or equal to 35%, QRS duration greater than or equal to 0.12 seconds, atrial fibrillation and NYHA class 3 or 4 heart failure symptoms on optimal medical therapy (considered a class 2a indication with level B evidence)

3. Patients with an left ventricular ejection fraction less than or equal to 35%, NYHA class 3 or 4 heart failure symptoms on optimal medical therapy and who have frequent dependence on ventricular pacing (considered a class 2a indication with level B evidence)

4. Patients with an left ventricular ejection fraction less than or equal to 35%, NYHA class 1 or 2 heart failure symptoms on optimal medical therapy and who are undergoing implantation of a permanent pacemaker and or ICD with anticipated frequent ventricular pacing (considered a class 2b indication with level C evidence)

References

  1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW (2008). "ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons". Circulation. 117 (21): e350–408. doi:10.1161/CIRCUALTIONAHA.108.189742. PMID 18483207. Retrieved 2011-01-15. Unknown parameter |month= ignored (help)

Template:WH Template:WS